Research article summary (published 2 Oct 2002):

Generation and characterization of six single VP4 gene substitution reassortant rotavirus vaccine candidates: each bears a single human rotavirus VP4 gene encoding P serotype 1A[8] or 1B[4] and the remaining 10 genes of rhesus monkey rotavirus MMU18006 or bovine rotavirus UK.

Full Abstract

The global disease burden of rotavirus diarrhea in infants and young children has stimulated interest in the biological and clinical characteristics of these agents, leading to intensive efforts to develop a vaccine. A rhesus rotavirus (RRV)-based quadrivalent vaccine ("RotaShield") was licensed and administered to about 1 million infants and found to be highly effective. However, it was withdrawn because of a link with intussusception. This vaccine was developed according to a modified "Jennerian" approach in which one of the two major outer capsid proteins (VP7) shares neutralization specificity with one of the four epidemiologically important human rotavirus serotypes. The other outer capsid protein (VP4) is derived solely from RRV and is distinct from the VP4 of the four human rotavirus serotypes of epidemiologic importance. In an effort to further increase the immunogenicity of the existing VP7-based RRV quadrivalent vaccine, we generated three single VP4 gene substitution reassortant rotavirus candidate vaccines, each of which bears a single human rotavirus VP4 gene encoding P serotype 1A[8] or 1B[4] specificity while the remaining 10 genes are derived from the rhesus rotavirus. By incorporating one or two of these strains into the quadrivalent vaccine, a pentavalent or hexavalent RRV-based vaccine could be formulated thus providing antigenic coverage not only for VP7 serotype 1, 2, 3 and 4 but also for VP4 serotype 1A[8] or 1B[4], thus possibly augmenting its immunogenicity. Similarly, three single VP4 gene (P1A[8] or P1B[4]) substitution reassortants have also been generated in a background of 10 bovine (UK) rotavirus genes for addition to a second generation UK-based quadrivalent vaccine.

Author information

Author/s: Hoshino, Yasutaka (Y); Jones, Ronald W (RW); Chanock, Robert M (RM); Kapikian, Albert Z (AZ);

Affiliation: Epidemiology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6308, 50 South Drive MSC 8026, Bethesda, MD 20892-8026, USA. thoshino(-atsign-)niaid.nih.gov

Journal and publication information

Publication Type: Journal Article

Journal: Vaccine (Vaccine), published in Netherlands. (Language: eng)

Reference: 2002-Oct; vol 20 (issue 29-30) : pp 3576-84

Dates: Created 2002/09/25; Completed 2003/04/11; Revised 2004/11/17;

PMID: 12297404, status: MEDLINE (last retrieved date: 2/18/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Animals Antigens, Viral Capsid Proteins - genetics; immunology Cattle - virology Cells, Cultured Cercopithecus aethiops Guinea Pigs

Guinea Pigs Immunization Macaca mulatta - virology Reassortant Viruses - immunology Rotavirus - classification; genetics Rotavirus Vaccines - immunology Serotyping

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: Antigens, Viral (0) ; Capsid Proteins (0) ; Rotavirus Vaccines (0) ; VP4 protein, Rotavirus (0) ; VP7 protein, Rotavirus (0)

Related articles

These are the most related articles currently in our database:

• Construction and characterization of rhesus monkey rotavirus (MMU18006)- or bovine rotavirus (UK)-based serotype G5, G8, G9 or G10 single VP7 gene substitution reassortant candidate vaccines. 18 Jun 2003
• Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine. 29 Jan 2007
• Characterization of neutralization specificities of outer capsid spike protein VP4 of selected murine, lapine, and human rotavirus strains. 18 Jul 2002
• The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants. 29 Jun 2006
• Human rotavirus strains bearing VP4 gene P[6] allele recovered from asymptomatic or symptomatic infections share similar, if not identical, VP4 neutralization specificities. 8 Nov 2003
• Porcine rotavirus strain Gottfried-based human rotavirus candidate vaccines: construction and characterization. 14 Mar 2005
• Molecular characterization of novel G5 bovine rotavirus strains. 21 Aug 2006
• Molecular and serologic characterization of novel serotype G8 human rotavirus strains detected in Blantyre, Malawi. 30 Aug 2000
• Production of two vaccinating recombinant rotavirus proteins in the milk of transgenic rabbits. 29 Nov 2005

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a larger map of 100+ related articles.